Pace-and-Wait for Atrial Fibrillation A Pharmacoelectric Antiarrhythmic Strategy
Heart Rhythm O2 · 2026-11
DOI: 10.1016/j.hroo.2026.11.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm O2, 2026-11. Verfasst von Nicole Habel und 6 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Contemporary atrial fibrillation (AF) management relies on antiarrhythmic drugs, catheter ablation, and rate-control strategies, each limited by suboptimal long-term efficacy, and treatment-related adverse effects. Pacemaker therapy has traditionally been reserved for AF patients undergoing AV node ablation and is generally regarded as a last resort rate-control therapy. Concept We propose "pace-and-wait" as a novel, mechanistically guided pharmacoelectric strategy that combines accelerated rate pacing with comprehensive atrial and ventricular conduction system pacing (CSP) to provide improved rate control without AV node ablation. This approach leverages complementary mechanisms: correction of interatrial conduction delay via Bachmann Bundle pacing, preservation of physiologic ventricular activation, and reduction of intracardiac filling pressures and rhythm irregularity through an elevated rate floor paired with a pharmacologic ceiling. The "pace-and-wait" strategy is intended to exert a primary antiarrhythmic effect by directly targeting key mechanisms of AF initiation and perpetuation, including atrial stretch, repolarization heterogeneity, and irregular cardiomyocyte calcium handling.
Implications
Excessive heart rate suppression, particularly in patients with normal ejection fraction, contributes to both AF and heart failure with preserved ejection fraction, supporting a shift from rate suppression toward physiologic rate support. Comprehensive CSP enables implementation of a higher rate floor that mitigates bradycardia, a common side effect of pharmacologic rate-control.
Conclusion
Pharmacoelectric therapy with comprehensive CSP has the potential to redefine the role of pacing in AF, from a last-resort intervention to a primary strategy aiming to modify the arrhythmogenic substrate through improved hemodynamics. Prospective randomized studies are needed to establish the clinical efficacy, and generalizability of this concept.
Zitieren
APA
Habel, N., Joza, J., Lumens, J., Infeld, M., Vernooy, K., Lustgarten, D., & Meyer, M. (2026). Pace-and-Wait for Atrial Fibrillation A Pharmacoelectric Antiarrhythmic Strategy. Heart Rhythm O2. https://doi.org/10.1016/j.hroo.2026.11.005
Vancouver
Habel N, Joza J, Lumens J, Infeld M, Vernooy K, Lustgarten D, et al. Pace-and-Wait for Atrial Fibrillation A Pharmacoelectric Antiarrhythmic Strategy. Heart Rhythm O2. 2026. doi:10.1016/j.hroo.2026.11.005
BibTeX
@article{Habel2026,
author = {Habel, Nicole and Joza, Jacqueline and Lumens, Joost and Infeld, Margaret and Vernooy, Kevin and Lustgarten, Daniel and Meyer, Markus},
title = {Pace-and-Wait for Atrial Fibrillation A Pharmacoelectric Antiarrhythmic Strategy},
journal = {Heart Rhythm O2},
year = {2026},
doi = {10.1016/j.hroo.2026.11.005}
}
EUVIMED